

#4 01-28-02

GP/1645

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/02. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/006,290
Filing Date	October 22, 2001
First Named Inventor	Jay WOHLGEMUTH, et al.
Group Art Unit	1645
Examiner Name	To Be Assigned
Attorney Docket No.	506612000100

RECEIVED

JAN 30 2002

Total Number Of Pages In This Submission

15

TECH CENTER 1600/2900

ENCLOSURES (check all that apply)

- | | | |
|--|--|---|
| <input type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Assignment Papers
(for an Application) | <input type="checkbox"/> After Allowance Communication to Group |
| <input type="checkbox"/> Fee Attached | <input type="checkbox"/> Drawing(s) | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences |
| <input type="checkbox"/> Amendment / Reply | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to Group
(Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final | <input type="checkbox"/> Petition | <input type="checkbox"/> Proprietary Information |
| <input type="checkbox"/> Affidavits/declarations | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Status Letter |
| <input type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Power of Attorney, Revocation
Change of Correspondence Address | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): RETURN RECEIPT POSTCARD |
| <input type="checkbox"/> Express Abandonment Request | <input type="checkbox"/> Terminal Disclaimer | |
| | <input type="checkbox"/> Request for Refund | |
| Information Disclosure | | |
| <input checked="" type="checkbox"/> Statement - 3 pgs IN DUPL
PTO-1449 - 4 pgs IN DUPL with
87 references attached | <input type="checkbox"/> CD, Number of CD(s) _____ | |
| <input type="checkbox"/> Certified Copy of Priority Document(s) | Remarks | |
| <input type="checkbox"/> Response to Missing Parts/
Incomplete Application | | |
| <input type="checkbox"/> Response to Missing Parts
under 37 CFR 1.52 or 1.53 | | |

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual Name	Morrison & Foerster LLP 425 Market Street, San Francisco, CA 94105-2842 Michael R. Ward (Reg. No. 38,651)
Signature	Michael R. Ward
Date	January 24, 2002

CERTIFICATE OF MAILING BY "EXPRESS MAIL"


Express Mail Label No.: EL 903 973 889

Date of Deposit: January 24, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

EL 903973889US

CHASE J. TROMBELLA



PATENT
Docket No. 506612000100

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EL 903 973 889

Date of Deposit: January 24, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.


CHASE J. TROMBELLA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Jay WOHLGEMUTH, et al.

Serial No.: 10/006,290

Filing Date: October 22, 2001

For: LEUKOCYTE EXPRESSION
PROFILING

Examiner: To Be Assigned

Group Art Unit: 1645

INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

RECEIVED
JAN 30 2002
TECH CENTER 1600/2900

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☒ **Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.**
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee. Accordingly, a Petition requesting consideration of the Information Disclosure Statement, an authorization to charge our deposit account, and a Certification under 37 C.F.R. § 1.97(e) are provided herein.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is to the best of my knowledge and is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 506612000100. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: January 24, 2002

Respectfully submitted,

By: Michael R. Ward
Michael R. Ward
Registration No. 38,651

Morrison & Foerster LLP
425 Market Street
San Francisco, California 94105-2482
Telephone: (415) 268-6237
Facsimile: (415) 268-7522

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION


(Use several sheets if necessary)

Docket Number **506612000100**Application Number **10/006,290**

Applicant

J. Wohlgemuth et al.

Filing Date 10/22/2001

Group Art Unit **1645**Mailing Date **January 24, 2002**

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	2/26/80	4,190,535	Luderer et al.			
	2.	9/21/82	4,350,593	Kessler			
	3.	6/14/88	4,751,001	Saunders			
	4.	6/27/89	4,843,155	Chomczynski			
	5.	4/4/89	4,818,418	Saunders			
	6.	3/13/90	4,908,318	Lerner			
	7.	10/1/91	5,053,134	Luderer et al.			
	8.	9/1/92	5,143,854	Pirrung et al.			
	9.	6/1/93	5,215,882	Bahl et al.			
	10.	2/28/95	5,393,672	Van Ness et al.			
	11.	10/17/95	5,459,037	Sutcliffe et al.			
	12.	1/30/96	5,487,970	Rowley et al.			
	13.	1/13/98	5,707,807	Kato			
	14.	2/24/98	5,721,351	Levinson			
	15.	9/15/98	5,807,522	Brown et al.			
	16.	11/17/98	5,837,832	Chee et al.			
	17.	9/28/99	5,958,342	Gamble et al.			
	18.	9/28/99	5,958,688	Eberwine et al.			
	19.	10/26/99	5,973,137	Heath			
	20.	11/30/99	5,994,076	Chenchik et al.			
	21.	12/21/99	6,004,755	Wang			
	22.	2/1/00	6,020,186	Henco et al.			
	23.	3/7/00	6,033,860	Lockhart et al.			
	24.	3/21/00	6,040,138	Lockhart et al.			
	25.	4/11/00	6,048,695	Bradley et al.			
	26.	4/11/00	6,048,709	Falb			
	27.	5/09/00	6,060,240	Kamb et al.			

EXAMINER: (examiner)


DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number **506612000100**Application Number **10/006,290**

Applicant

J. Wohlgemuth et al.

Filing Date 10/22/2001

Group Art Unit **1645**Mailing Date **January 24, 2002**

28.	5/23/00	6,066,322	Levinson			
29.	5/23/00	6,066,498	Levinson			
30.	7/4/00	6,084,083	Levinson			
31.	7/11/00	6,087,112	Dale			
32.	7/11/00	6,087,477	Falb et al.			
33.	7/18/00	6,090,556	Kato			
34.	8/8/00	6,099,823	Falb			
35.	9/26/00	6,124,433	Falb et al.			
36.	11/14/00	6,146,828	Lapidus et al.			
37.	12/5/00	6,156,887	Levinson			
38.	1/2/01	6,168,933 B1	Kaser et al.			
39.	2/13/01	6,187,534 B1	Strom et al.			
40.	3/20/01	6,204,371 B1	Levinson			
41.	4/17/01	6,218,122 B1	Friend et al.			
42.	6/5/01	6,242,185 B1	Kaser et al.			
43.	6/12/01	6,245,334 B1	Seilhammer et al.			
44.	6/12/01	6,245,526 B1	Yue et al.			
45.	6/12/01	6,245,527 B1	Busfield et al.			
46.	6/19/01	6,248,527 B1	Chen et al.			
47.	6/19/01	6,248,528 B1	Chen et al.			
48.	6/26/01	6,251,597 B1	Shyjan			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO	
	49.	8/21/97	WO 97/30065	WIPO				
	50.	3/4/99	WO 99/10536	WIPO				
	51.	10/21/99	WO 99/52541	WIPO				
	52.	11/11/99	WO 99/57130	WIPO				
	53.	8/10/00	WO 00/46372	WIPO				

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION


(Use several sheets if necessary)

Docket Number **506612000100**Application Number **10/006,290**

Applicant

J. Wohlgemuth et al.

Filing Date 10/22/2001

Group Art Unit **1645**Mailing Date **January 24, 2002**

		9/8/00	WO 00/52209	WIPO				
	55.	3/22/01	WO 01/20004	WIPO				
	56.	4/5/01	WO 01/23426	WIPO				
	57.	4/5/01	WO 01/23564	WIPO				
	58.	4/26/01	WO 01/29269	WIPO				
	59.	5/10/01	WO 01/32927	WIPO				

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	60.	Alizadeh, A. A. et al. "Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling" <i>Nature</i> 403 (2000): 503-11.
	61.	Alizadeh, A. et al. "Probing Lymphocyte Biology by Genomic-Scale Gene Expression Analysis" <i>J. Clin. Immun.</i> 18 (1998): 373-379.
	62.	Alizadeh, A. et al. "The Lymphochip: A Specialized cDNA Microarray for the Genomic-scale Analysis of Gene Expression in Normal and Malignant Lymphocytes" <i>Cold Spring Harbor Symposia on Quantitative Biology</i> 54, (New York: Cold Spring Harbor Laboratory Press) (1999): 71- 78.
	63.	Arnett, F. C. et al. "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis" <i>Arthritis Rheum</i> 31 (1988): 315-24.
	64.	Bombardier, C. et al. and the Committee on Prognosis Studies in SLE. "Derivation of the SLEDAI, A Disease Activity Index for Lupus Patients" <i>Arthritis Rheum.</i> 35 (1992): 630-640.
	65.	Damas, J. K. et al. "Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure--modulatory effect of intravenous immunoglobulin" <i>J. Am. Coll. Cardiol.</i> 38 (2001): 187-93.
	66.	Edman, C. F. et al. "Electric field directed nucleic acid hybridization on microchips" <i>Nucleic Acids Res.</i> 25 (1997): 4907-14.
	67.	Felson, D. T. et al. "American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis" <i>Arthritis Rheum.</i> 38 (1995): 727-35.
	68.	Golub, T. R. et al. "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring" <i>Science</i> 286 (1999): 531-7.
	69.	Gullestad, L. et al. "Effect of High- Versus Low-Dose Angiotensin Converting Enzyme Inhibition on Cytokine Levels in Chronic Heart Failure" <i>J. Am. Coll. Cardiol.</i> 34 (1999): 2061-7.
	70.	Hastie, T. et al. "'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns" <i>Genome Biol.</i> 1 (2000): RESEARCH0003.
	71.	Heller, R. A. et al. "Discovery and analysis of inflammatory disease-related genes using cDNA microarrays" <i>Proc. Natl. Acad. Sci. U.S.A.</i> 94 (1997): 2150-2155.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION


(Use several sheets if necessary)

Docket Number **506612000100**Application Number **10/006,290**

Applicant

J. Wohlgemuth et al.

Filing Date 10/22/2001

Group Art Unit **1645**Mailing Date **January 24, 2002**

- | | |
|-----|---|
| | Khan, J. et al. "Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks" <i>Nat. Med.</i> 7 (2001): 673-9. |
| 73. | Li, B. et al. "Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine" <i>N. Engl. J. Med.</i> 344 (2001): 947-954. |
| 74. | Mohler, E. R. 3rd et al. "Role of Cytokines in the Mechanism of Action of Amlodipine: The PRAISE Heart Failure Trial" <i>J. Am. Coll. Cardiol.</i> 30 (1997): 35-41. |
| 75. | Perou, C. M. et al. "Molecular portraits of human breast tumours" <i>Nature</i> 406 (2000): 747-52. |
| 76. | Pruitt, K. D. et al. "Introducing RefSeq and LocusLink: curated human genome resources at the NCBI" <i>Trends Genet.</i> 16 (2000): 44-47. |
| 77. | Raychaudhuri, S. et al. "Basic microarray analysis: grouping and feature reduction" <i>Trends Biotechnol.</i> 19 (2001): 189-193. |
| 78. | Shirali, G. S. et al. "Association of viral genome with graft loss in children after cardiac transplantation" <i>N. Engl. J. Med.</i> 344 (2001): 1498-503. |
| 79. | Staudt, L. M. and P. O. Brown. "Genomic Views of the Immune System" <i>Annu. Rev. Immunol.</i> 18 (2000): 829-859. |
| 80. | Tan, E. M. et al. "The 1982 revised criteria for the classification of systemic lupus erythematosus" <i>Arthritis Rheum.</i> 25 (1982): 1271-7. |
| 81. | Tan, LamChin et al. "Sequential Monitoring of Peripheral T-Lymphocyte Cytokine Gene Expression in the Early Post Renal Allograft Period" <i>Transplantation</i> 71 (2001): 751-759. |
| 82. | Torre-Amione, G. et al. "Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD)" <i>J. Am. Coll. Cardiol.</i> 27 (1996): 1201-6. |
| 83. | Tsutamoto, T. et al. "Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure" <i>J. Am. Coll. Cardio.</i> 35 (2000): 714-21. |
| 84. | Umek, R. M. et al. "Electronic detection of nucleic acids: a versatile platform for molecular diagnostics" <i>J. Mol. Diagn.</i> 3 (2001): 74-84. |
| 85. | Vignali D. "Multiplexed particle-based flow cytometric assays" <i>J. Immun. Meth.</i> 243 (2000): 243-55. |
| 86. | Welsh, J. B. et al. "Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer" <i>Proc. Natl. Acad. Sci. U.S.A.</i> 98 (2001): 1176-81. |
| 87. | Westin L. et al. "Anchored multiplex amplification on a microelectronic chip array" <i>Nat. Biotechnol.</i> 18 (2000): 199-204. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.